These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 9631992)
61. Toenail abnormalities and onychomycosis in chronic venous insufficiency of the legs: should we treat? Shemer A; Nathansohn N; Kaplan B; Trau H J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):279-82. PubMed ID: 18269594 [TBL] [Abstract][Full Text] [Related]
62. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Gupta AK; Gregurek-Novak T Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230 [TBL] [Abstract][Full Text] [Related]
63. [The treatment of extensive onychomycosis in aged patients]. Maleszka R; Adamski Z Wiad Parazytol; 2001; 47(4):817-22. PubMed ID: 16886433 [TBL] [Abstract][Full Text] [Related]
64. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis. Schaller M; Sigurgeirsson B; Sarkany M Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059 [TBL] [Abstract][Full Text] [Related]
65. Clinical and pharmacokinetic studies of continuous itraconazole for the treatment of onychomycosis. Kawada A; Aragane Y; Tezuka T J Dermatol; 2004 Feb; 31(2):104-8. PubMed ID: 15160863 [TBL] [Abstract][Full Text] [Related]
66. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Havu V; Brandt H; Heikkilä H; Hollmen A; Oksman R; Rantanen T; Saari S; Stubb S; Turjanmaa K; Piepponen T Br J Dermatol; 1997 Feb; 136(2):230-4. PubMed ID: 9068738 [TBL] [Abstract][Full Text] [Related]
67. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. Gupta AK; Lynde CW; Konnikov N J Am Acad Dermatol; 2001 Mar; 44(3):485-91. PubMed ID: 11209119 [TBL] [Abstract][Full Text] [Related]
68. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. Bohn M; Kraemer K J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709 [TBL] [Abstract][Full Text] [Related]
69. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. Bohn M; Kraemer KT J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135 [TBL] [Abstract][Full Text] [Related]
70. Efficacy of fluconazole for the treatment of onychomycosis. Brown SJ Ann Pharmacother; 2009 Oct; 43(10):1684-91. PubMed ID: 19776299 [TBL] [Abstract][Full Text] [Related]
71. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. Tschen EH; Bucko AD; Oizumi N; Kawabata H; Olin JT; Pillai R J Drugs Dermatol; 2013 Feb; 12(2):186-92. PubMed ID: 23377392 [TBL] [Abstract][Full Text] [Related]
72. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348 [TBL] [Abstract][Full Text] [Related]
73. The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis. Potter LP; Mathias SD; Raut M; Kianifard F; Tavakkol A Health Qual Life Outcomes; 2006 Aug; 4():50. PubMed ID: 16911778 [TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetics of terbinafine in the nail. Finlay AY Br J Dermatol; 1992 Feb; 126 Suppl 39():28-32. PubMed ID: 1531925 [TBL] [Abstract][Full Text] [Related]
75. Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. Jones T; Tavakkol A Antimicrob Agents Chemother; 2013 Jun; 57(6):2684-9. PubMed ID: 23545529 [TBL] [Abstract][Full Text] [Related]
76. Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. Firooz A; Khamesipour A; Dowlati Y J Dermatolog Treat; 2003 Jun; 14(2):95-8. PubMed ID: 12775316 [TBL] [Abstract][Full Text] [Related]
77. Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis. Feldman SR; Vlahovic TC; Joseph WS; Daniel CR; Elewski B; Rich P; Lipner SR J Drugs Dermatol; 2024 Feb; 23(2):110-112. PubMed ID: 38306131 [TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics of fluconazole in loggerhead sea turtles (Caretta caretta) after single intravenous and subcutaneous injections, and multiple subcutaneous injections. Mallo KM; Harms CA; Lewbart GA; Papich MG J Zoo Wildl Med; 2002 Mar; 33(1):29-35. PubMed ID: 12216790 [TBL] [Abstract][Full Text] [Related]
79. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Figueiredo Souza LW; Souza SV; Botelho AC Dermatol Ther; 2014; 27(1):43-7. PubMed ID: 24502311 [TBL] [Abstract][Full Text] [Related]
80. Medium-term antifungal effects of methylene blue versus flavin mononucleotide in the treatment of moderate toenail onychomycosis. Gómez C; Schuele G; Alberdi E Mycoses; 2024 Jan; 67(1):e13661. PubMed ID: 37840157 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]